More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag into registrational testing in one of the most important oncology disease ...
Luci indicated the company is focused on securing additional funding opportunities to support the Phase 3 ibezapolstat clinical trial program and expects further updates on funding initiatives in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback